Regeneron and Sanofi’s anti-inflammatory drug Dupixent has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute involving the HIV drug dolutegravir.
ImmunityBio shared positive results from its clinical trial on its IL-15 superagonist Anktiva (N-803) to treat people living with human immunodeficiency virus (HIV).
Scientists believe that, perhaps, Alzheimer’s disease is a cause of not just beta-amyloid accumulation but, digging more deeply, immune system dysfunction.
The company initiated the use of splenic nerve simulation last month as part of a small clinical trial at the NHS Greater Glasgow & Clyde Health Board in Scotland.
Incyte’s decision follows consultation with the FDA, where it decided that it could not support any confirmatory studies that might be required in the future given the limited time frame.
The company’s focus is to find somebody with considerable pharmaceutical industry experience to help advance regulatory and commercialization initiatives for leronlimab.
The amount will be used to enhance research and development efforts for KYV-101 that has a strong potential to treat different types of autoimmune illnesses.
The Phase III MOMENTUM trial showed that momelotinib was able to meet its primary endpoint by week 24, specifically a TSS reduction of over 50% compared to the baseline figures.
The FDA cited data demonstrating that both treatments are not likely to be potent against omicron and should not be authorized for use in any U.S. state, territory, and jurisdiction for the time being.
The U.S. Food and Drug Administration has approved SKYRIZI (risankizumab-rzaa), AbbVie’s proposed treatment for adults diagnosed with active psoriatic arthritis (PsA).
